Investigational drug · Phase 2
YY003
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Moderate to Severe Glabellar Lines.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 8, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
1
Any phase or sponsor naming "YY003"
First trial start
2025
Jan 9, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "YY003", any sponsor or status.
Conditions studied
As listed on its trial records.
- Moderate to Severe Glabellar Lines
Largest trials
Live from ClinicalTrials.gov: studies naming "YY003" as an intervention, largest first.
- A Study to Investigate the Safety and Efficacy of YY003 in Adults With Moderate to Severe Glabellar LinesPivotal-lookingCompleted
Chongqing Claruvis Pharmaceutical Co., Ltd.Industry
NCT06481475 · 153 participants · Start Jan 9, 2025 · Primary completion Oct 22, 2025
Drug: YY003; Vehicle Control · For: Moderate to Severe Glabellar Lines
Sites: Sydney, Australia; Melbourne, Australia · 3 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Moderate to Severe Glabellar Lines
- CorabotaseIPN10200Phase 37 trials
Ipsen · Moderate to Severe Glabellar Lines, Spasticity, Moderate to Severe Upper Facial Lines
- YY001Recombinant botulinum toxin type A, Rcombinant botulinum neurotoxin type APhase 33 trials
Chongqing Claruvis Pharmaceutical Co., Ltd. · Upper Limb Spasticity, Moderate to Severe Glabellar Lines
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.